The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1
Open accessAbstract
BACKGROUND: An efavirenz-based regimen (with a 600-mg dose of efavirenz, known as EFV600) was the World Health Organization preferred first-line treatment for human immunodeficiency virus type 1 (HIV-1) infection until June 2018. Given concerns about side effects, dolutegravir-based and low-dose efavirenz-based combinations have been considered as first-line treatments for HIV-1 in resource-limited settings. METHODS: We conducted an open-label, multicenter, randomized, phase 3 noninferiority trial in Cameroon. Adults with HIV-1 infection who had not received antiretroviral therapy and had an HIV-1 RNA level (viral load) of at least 1000 copies per milliliter were randomly assigned to receive either dolutegravir or the reference treatment of low-dose efavirenz (a 400-mg dose, known as EFV400), combined with tenofovir and lamivudine. The primary end point was the proportion of participants with a viral load of less than 50 copies per milliliter at week 48, on the basis of the Food and Drug Administration snapshot algorithm. The difference between treatment groups was calculated, and noninferiority was tested with a margin of 10 percentage points. RESULTS: A total of 613 participants received at least one dose of the assigned regimen. At week 48, a viral load of less than 50 copies per milliliter was observed in 231 of 310 participants (74.5%) in the dolutegravir group and in 209 of 303 participants (69.0%) in the EFV400 group, with a difference of 5.5 percentage points (95% confidence interval [CI], -1.6 to 12.7; P<0.001 for noninferiority). Among those with a baseline viral load of at least 100,000 copies per milliliter, a viral load of less than 50 copies per milliliter was observed in 137 of 207 participants (66.2%) in the dolutegravir group and in 123 of 200 participants (61.5%) in the EFV400 group, with a difference of 4.7 percentage points (95% CI, -4.6 to 14.0). Virologic failure (a viral load of >1000 copies per milliliter) was observed in 3 participants in the dolutegravir group (with none acquiring drug-resistance mutations) and in 16 participants in the EFV400 group. More weight gain was observed in the dolutegravir group than in the EFV400 group (median weight gain, 5.0 kg vs. 3.0 kg; incidence of obesity, 12.3% vs. 5.4%). CONCLUSIONS: In HIV-1-infected adults in Cameroon, a dolutegravir-based regimen was noninferior to an EFV400-based reference regimen with regard to viral suppression at week 48. Among participants who had a viral load of at least 100,000 copies per milliliter when antiretroviral therapy was initiated, fewer participants than expected had viral suppression. (Funded by Unitaid and the French National Agency for AIDS Research; NAMSAL ANRS 12313 ClinicalTrials.gov number, NCT02777229.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WARE, J. E., KOSINSKI, M., & KELLER, S. D. (1996) · Medical Care · doi:10.1097/00005650-199603000-00003 · Cited by 17,392
Henry, J. D., & Crawford, J. R. (2005) · British Journal of Clinical Psychology · doi:10.1348/014466505x29657 · Cited by 5,801
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215541 · Cited by 876
Raffi, F., Rachlis, A., Stellbrink, H.-J., Hardy, W. D., Torti, C., Orkin, C., Bloch, M., Podzamczer, D., Pokrovsky, V., Pulido, F., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61853-4 · Cited by 548
Sax, P. E., DeJesus, E., Mills, A., Zolopa, A., Cohen, C., Wohl, D., Gallant, J. E., Liu, H. C., Zhong, L., Yale, K., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60917-9 · Cited by 444
Development and validation of a self-completed HIV symptom index
Justice, A. C., Holmes, W., Gifford, A. L., Rabeneck, L., Zackin, R., Sinclair, G., Weissman, S., Neidig, J., Marcus, C., Chesney, M., et al. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00449-8 · Cited by 439
Gupta, R. K., Gregson, J., Parkin, N., Haile-Selassie, H., Tanuri, A., Andrade Forero, L., Kaleebu, P., Watera, C., Aghokeng, A., Mutenda, N., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30702-8 · Cited by 414
DeJesus, E., Rockstroh, J. K., Henry, K., Molina, J.-M., Gathe, J., Ramanathan, S., Wei, X., Yale, K., Szwarcberg, J., White, K., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60918-0 · Cited by 347
Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals
Clifford, D. B., Evans, S., Yang, Y., Acosta, E. P., Goodkin, K., Tashima, K., Simpson, D., Dorfman, D., Ribaudo, H., Gulick, R. M., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-10-200511150-00008 · Cited by 270
Hamers, R. L., Schuurman, R., Sigaloff, K. C., Wallis, C. L., Kityo, C., Siwale, M., Mandaliya, K., Ive, P., Botes, M. E., Wellington, M., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70255-9 · Cited by 190
Cited by
Obesity and weight gain in persons with HIV
Bailin, S. S., Gabriel, C. L., Wanjalla, C. N., & Koethe, J. R. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00483-5 · Cited by 213
McCann, K., Shah, S., Hindley, L., Hill, A., Qavi, A., Simmons, B., Serenata, C., Sokhela, S., & Venter, W. D. F. (2021) · AIDS · doi:10.1097/qad.0000000000002930 · Cited by 72
Metadata
- Authors
- The NAMSAL ANRS 12313 Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-08-29
- Volume
- 381
- Issue
- 9
- Pages
- 816-826
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2995015948
- Cited by
- 326
- References
- 18
- FWCI
- 23.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1. https://app.cochat.ai/papers/10.1056/nejmoa1904340
- The paper
- The NAMSAL ANRS 12313 Study Group. (2019). Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1904340
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.